IRCCS San Raffele
Milan, Italy, 20132
Location status: Recruiting
Location contact
Elisa Canu, PhD
CONTACT
Massimo Filippi, MD
CONTACT
NCT Number: NCT07272811
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers.
The Neurocognitive Assessment Platform 4 Alzheimer (NAP4A) study aims to create a digital platform for the early detection of amnestic mild cognitive impairment (MCIa), considered an intermediate stage between normal aging and dementia. The platform uses non-invasive biometric tools, including EEG, blood flow sensors, and eye-tracking devices, to collect neurophysiological and behavioral data.
The study will involve 100 participants aged 55 to 80, divided into two groups: one with individuals diagnosed with MCIa and a control group of healthy participants. Over 12 months, regular assessments will be conducted to identify markers that predict the progression from MCIa to AD. The goal is to develop advanced diagnostic tools that support early and targeted interventions.
Interested in participating?
Request Info55 year–80 year
All sexes
Observational
Milan, Italy, 20132
Location status: Recruiting
Elisa Canu, PhD
CONTACT
Massimo Filippi, MD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
common to both experimental groups:
Specfic inclusion criteria for Healthy Controls recruitment:
Specific inclusion criteria for aMCI recruitment:
Exclusion criteria
Time frame: 12 months
To create a digital tool for fast and easy cognitive and behavioral assessment to examine the preclinical stage of Alzheimer's: Neurocognitive Assessment Platform 4 Alzheimer (NAP4A)
Time frame: 12 months
To identify aMCI individuals at an early stage who are at risk of progression to AD using the Neurocognitive Assessment Platform 4 Alzheimer (NAP4A)
Time frame: 12 months
To develop probability markers that predict the likelihood of aMCI individuals converting to AD based on data from the Neurocognitve Assessment Platform 4 Alzheimer
Contact information is provided by the study sponsor or research team.
Elisa Canu, PhD
CONTACT
Virginia Sanchini, PhD
CONTACT
IRCCS San Raffaele
Other
Acronym: NAP4A2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07235111
ALS (Amyotrophic Lateral Sclerosis), Alzheimer Disease
Genoa, Italy
View Trial DetailsNCT06335836
AD, Alzheimer Disease
Nanjing, China, Jiangsu, China
View Trial DetailsNCT04360200
Alzheimer Disease, Brain Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT07630688
Alzheimer Disease, Behavior
Antalya, Muratpaşa, Turkey (Türkiye)
View Trial Details